Spiramycin is comparable to oxytetracycline in eradicating H. pylori when given with ranitidine bismuth citrate and metronidazole
- 1 May 1999
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 13 (5) , 651-659
- https://doi.org/10.1046/j.1365-2036.1999.00517.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcerAlimentary Pharmacology & Therapeutics, 1998
- Effects of ranitidine bismuth citrate on gastric acid secretion and gastrin release in subjects with and without Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1996
- The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pyloriAlimentary Pharmacology & Therapeutics, 1996
- Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture.Alimentary Pharmacology & Therapeutics, 1996
- The Treatment ofHelicobacter pyloriInfection in the Management of Peptic Ulcer DiseaseNew England Journal of Medicine, 1995
- Spiramycin in triple therapy of Helicobacter pylori‐associated peptic ulcer disease. An open pilot study with 12‐month follow‐upAlimentary Pharmacology & Therapeutics, 1995
- Antibacterial Treatment of Gastric Ulcers Associated withHelicobacter pyloriNew England Journal of Medicine, 1995
- Phospholipase activity ofHelicobacter pylori and its inhibition by bismuth saltsDigestive Diseases and Sciences, 1993
- Clarithromycin and omeprazole for Helicobacter pyloriThe Lancet, 1992
- The effect of GR122311X, a bismuth compound with H2‐antagonist activity, on 24‐hour intragastric acidityAlimentary Pharmacology & Therapeutics, 1991